Experts express alarm that GLP-1 RAs may trigger or worsen eating disorders. But is there any role they might play in binge ...

Expanding Medicare coverage for glucagon-like peptide 1 (GLP-1) receptor agonists could significantly reduce obesity-related ...

Both GLP-1 RAs and SGLT2is are associated with a reduced risk for Alzheimer disease and related dementias among people with T2D.

Glucagon-like peptide 1 receptor agonist therapy over a 12-month period is safe and effective in treating weight regain ...

Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

Among US adults without diabetes, the use of GLP-1 RAs increased from 2018 to 2022, reaching annual prevalence of 0.4% in 2022.

During oral arguments, the defendants contended that the plaintiffs could not support their allegations that Novo Nordisk and ...

Increased awareness and knowledge of GLP-1/GIP receptor agonists among women, with insights into public perspectives on ...

New research being presented at this year's European Congress on Obesity (ECO 2025, Malaga, Spain, 11–14 May) shows that ...

Both GLP-1 receptor agonists and SGLT2 inhibitors linked to reduced risk for ADRD, with no significant difference between them. (HealthDay News) — Both glucagon-like peptide-1 receptor agonists ...

This study found that using GLP-1 RAs and SGLT2is for type 2 diabetes treatment offers potential neuroprotections against Alzheimer disease and related dementias. HealthDay News — Both glucagon ...